Bharat Immunological & Biological Corporation Ltd () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Mercury Labs

Source Natural

Ajooni Biotech

Samrat Pharma

Vaishali Pharma

Bharat Immunolog

Amwill Health

Asston Pharmaceu

Zenith Drugs

Accretion Pha.

Curis Lifescien.

Why is Bharat Immunological & Biological Corporation Ltd ?

Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months

Poor long term growth as Net Sales has grown by an annual rate of -24.67% and Operating profit at -229.01% over the last 5 years
Low ability to service debt as the company has a high Debt to EBITDA ratio of -1.00 times

Negative results in Sep 23

NET SALES(9M) At INR 76.5 MM has Grown at -87.03%
OPERATING CASH FLOW(Y) Lowest at INR 0 MM
DEBT-EQUITY RATIO (HY) Highest at 83.16 %

Risky - No result in last 6 months

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -26.24%, its profits have fallen by -42.4%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -26.24% returns in the last 1 year, the stock has also underperformed BSE500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Bharat Immunolog for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Bharat Immunolog

-26.24%

-0.53

49.63%

Sensex

4.83%

0.41

11.83%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-24.67%

EBIT Growth (5y)

-170.32%

EBIT to Interest (avg)

-4.32

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.83

Sales to Capital Employed (avg)

0.83

Tax Ratio

20.41%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

-25.80%

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.07

EV to EBIT

-8.33

EV to EBITDA

-8.42

EV to Capital Employed

1.04

EV to Sales

19.53

PEG Ratio

Dividend Yield

ROCE (Latest)

-12.44%

ROE (Latest)

-22.96%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bearish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Loading Valuation Snapshot...

Here's what is working for Bharat Immunolog

Raw Material Cost

Fallen by -87.68% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Bharat Immunolog

Net Sales

At INR 76.5 MM has Grown at -87.03%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (INR MM)

Operating Cash Flow

Lowest at INR 0 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (INR MM)

Interest

At INR 20.87 MM has Grown at 21.27%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (INR MM)

Interest

Highest at INR 20.87 MM

in the last five periods and Increased by 21.27% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (INR MM)

Pre-Tax Profit

Lowest at INR -66.46 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (INR MM)

Pre-Tax Profit

At INR -66.46 MM has Fallen at -31.4%

over average net sales of the previous four periods of INR -50.58 MM

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (INR MM)

Net Profit

Lowest at INR -49.18 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (INR MM)

Net Profit

At INR -49.18 MM has Fallen at -36.96%

over average net sales of the previous four periods of INR -35.91 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (INR MM)

EPS

Lowest at INR -1.14

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (INR)

Debt-Equity Ratio

Highest at 83.16 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio

Lowest at 0.4%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio